M&T Bank
ACRS icon

M&T Bank’s Aclaris Therapeutics ACRS Stock Holding History

M&T Bank’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.6K Buy
10,516
+428
+4% +$1.91K ﹤0.01% 1734
2026
Q1 		$37.8K Buy
+10,088
New +$34K ﹤0.01% 1682

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

M&T Bank's ACRS Position: Q2 2026 in Review

M&T Bank increased its Aclaris Therapeutics (ACRS) stake by 4.2% in Q2 2026, buying an estimated $1.91K and bringing the position to 10,516 shares worth $55.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

M&T Bank first reported a position in ACRS in Q1 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • M&T Bank held 10,516 shares of Aclaris Therapeutics worth $55.6K as of Q2 2026.
  • M&T Bank bought 428 Aclaris Therapeutics shares in Q2 2026, an estimated $1.91K.
  • Aclaris Therapeutics made up ﹤0.01% of M&T Bank's portfolio in Q2 2026, its #1734 holding.
  • M&T Bank first reported a position in Aclaris Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.